The “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ) is also a therapy and research center for oncological and hematological diseases in childhood and adolescence. Its aim is to scientifically fathom the biology of childhood cancers and to closely link promising research approaches with patient care – from diagnosis to treatment and follow-up care.
The aim of the KiTZ Clinical Trial Unit (ZIPO) is to use state-of-the-art molecular diagnostic methods to identify target structures for personalised therapy. New phase I/II clinical studies are being developed and new therapeutic approaches are being tested. With this individualised approach, the study unit is assuming a pioneering role in Germany. The KiTZ Clinical Trial Unit is headed by Olaf Witt.
In the KiTZ Clinical Trial Unit, a multidisciplinary team looks after young cancer patients for whom standard treatment methods have not led to success. In clinical trials, these children and adolescents are given – whenever possible – access to new treatment options under controlled conditions.
Translation into new studies: New therapeutic approaches discovered in the preclinical program of the KiTZ are transferred into clinical research. A team of the KiTZ Clinical Trial Unit, consisting of specialised physicians, statisticians, project managers and data managers, develops innovative study protocols in cooperation with the Department of Statistics of the DKFZ and the NCT Study Center and coordinates its own academic studies within the existing pediatric oncology networks on a national and international level.